Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and extra fluids from the blood. For some, this decline in kidney function is associated with genetic factors. One genetic link that has been identified in recent years is a variation of the APOL1 gene, commonly found in people of African descent. It can increase the risk of developing a form of CKD known as APOL1-associated nephropathy, or APOL1-mediated kidney disease (AMKD).
If you have been diagnosed with AMKD or suspect that it might be a factor in your kidney disease, understanding the condition, its risks, and the potential benefits of clinical research can empower you to make informed decisions about your health.
Table of Contents
What is APOL1-mediated Kidney Disease (AMKD)?
The APOL1 gene is involved in the body’s immune system. Some people in certain populations, such as those of African, Caribbean, or Latin American descent may carry specific variants (G1 and G2) of the APOL1 gene that can increase their risk of kidney disease. Carrying two copies of variants has been associated with potential for significantly increased risk of developing CKD.
Not everyone with APOL1 gene variants will develop kidney disease. For those who do develop the disease, it can progress more rapidly and have a higher risk of kidney failure. This makes early intervention and management important.
Symptoms of AMKD
Like other forms of CKD, AMKD may not cause symptoms in its early stages. As kidney function worsens, symptoms may include:
- Fatigue or weakness
- Swelling (especially in the legs and feet) caused by fluid buildup
- Loss of appetite, nausea, or vomiting
- Difficulty concentrating
- High blood pressure that may be hard to control
Since many of these symptoms can overlap with other health conditions, it’s important to work with a healthcare provider to confirm an AMKD diagnosis, particularly if you are of African descent and have a family history of kidney disease.
Diagnosing AMKD
Diagnosing AMKD typically involves blood and urine tests to assess kidney function, as well as genetic testing to determine whether you carry high-risk APOL1 gene variants. If you are diagnosed with AMKD, your doctor may recommend lifestyle changes, medications, or other treatments to help manage the condition and delay kidney damage.
Why Participate in a Clinical Trial?
Clinical trials play a crucial role in discovering new treatments and improving our understanding of diseases. They allow researchers to test investigational therapies and study their effects on different populations. They offer access to investigational treatments before they become widely available.
Participating in a clinical trial gives you a chance to contribute to medical research that could benefit others living with AMKD in the future.
The AMPLITUDE Clinical Research Study
The AMPLITUDE study is a clinical research study specifically designed to study investigational treatment for AMKD. By participating, you could help researchers gain valuable insights into how to manage and potentially treat AMKD more effectively.
The study is currently enrolling adults ages 18-65 who meet certain criteria and are interested in taking part in AMKD research. Those who qualify will receive study-related care from a dedicated research team and have access to study-related medical assessments and investigational treatment.
How to Get Involved
If you or someone you know is living with AMKD, consider learning more about the AMPLITUDE study. Participating in a clinical trial provides a chance to make a difference in the future of kidney disease treatment.
Visit here to determine if the study may be a good fit for you. Taking this step contributes to a better understanding of AMKD for others.
Join the AMPLITUDE study today and take a proactive step in managing your AMKD.
References
American Kidney Fund. APOL-1 Mediated Kidney Disease
American Association of Kidney Patients. APOL 1 Gene
National Kidney Foundation. APOL1-Mediated Kidney Disease (AMKD)
Neph Cure for Rare Kidney Disease. APOL1 Kidney Disease
